UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: PR Newswire
Diverse and patient-focused data set comprises 17 abstracts including one oral presentationFeatures new data analyses for UCB's generalized myasthenia gravis (gMG) treatments, including post hoc and open-label extension results from the pivotal Phase 3 MycarinG study and additional Interim Analyses of RAISE-XT for the approved treatments RYSTIGGO®? (rozanolixizumab-noli) and ZILBRYSQ®? (zilucoplan)Data on BRIVIACT® (brivaracetam), FINTEPLA®? (fenfluramine), and STACCATO® alprazolam showcase commitment to patients and momentum of UCB's epilepsy and rare syndromes portfolioATLANTA, April 12, 2024 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.A total of 17 abstracts, including an oral presentation, will feature data from studies of four approve
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
- UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis SuppurativaPR Newswire
- BioIVT to Host Symposium and Workshop in Brussels on Advanced In Vitro ADME Methodologies [Yahoo! Finance]Yahoo! Finance
- FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations [Yahoo! Finance]Yahoo! Finance